Janiczek Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Janiczek Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6	Closed	-$738	–	1127
2023 Q4	$738	Hold	6	–	–	﹤0.01%	963
2023 Q3	$777	Sell	6 -5	-45%	-$666	﹤0.01%	938
2023 Q2	$1.36K	Sell	11 -3	-21%	-$404	﹤0.01%	809
2023 Q1	$2.04K	Hold	14	–	–	﹤0.01%	765
2022 Q4	$2.21K	Hold	14	–	–	﹤0.01%	760
2022 Q3	$2K	Hold	14	–	–	﹤0.01%	763
2022 Q2	$2K	Hold	14	–	–	﹤0.01%	780
2022 Q1	$2K	Sell	14 -7	-33%	-$1.02K	﹤0.01%	773
2021 Q4	$3K	Sell	21 -83	-80%	-$10.9K	﹤0.01%	780
2021 Q3	$14K	Buy	104 +11	+12%	+$1.66K	0.01%	514
2021 Q2	$17K	Sell	93 -3	-3%	-$520	0.01%	463
2021 Q1	$16K	Buy	96 +36	+60%	+$5.92K	0.01%	445
2020 Q4	$10K	Buy	60 +49	+445%	+$7.3K	﹤0.01%	477
2020 Q3	$2K	Buy	+11	New	+$1.36K	﹤0.01%	511

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Janiczek Wealth Management's JAZZ Position: Q1 2024 in Review

Janiczek Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 6 shares — an estimated $738 sold.

Janiczek Wealth Management first reported a position in JAZZ in Q3 2020 and held it in 14 quarters. The position peaked at $17K in Q2 2021. 481 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

Janiczek Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Janiczek Wealth Management sold 6 Jazz Pharmaceuticals shares in Q1 2024, an estimated $738.
Janiczek Wealth Management first reported a position in Jazz Pharmaceuticals in Q3 2020 and held it in 14 quarters.
Janiczek Wealth Management's Jazz Pharmaceuticals position peaked at $17K in Q2 2021.
481 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Janiczek Wealth Management's 13F filing for Q1 2024, filed 15 Apr 2024.